Karyopharm Therapeutics Inc. (KPTI)
NASDAQ: KPTI · Real-Time Price · USD
7.47
+0.33 (4.62%)
May 19, 2026, 4:00 PM EDT - Market closed
Karyopharm Therapeutics Stock Forecast
Stock Price Forecast
According to 7 analysts polled by S&P Global, Karyopharm Therapeutics stock has a consensus rating of "Buy" and an average price target of $13.5. The average 1-year stock price forecast is 80.72% higher than the current stock price, while the lowest is $7.00 (-6.29%) and the highest is $16 (+114.19%).
Price Target: $13.5 (+80.72%)
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for Karyopharm Therapeutics stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Dec '25 | Jan '26 | Feb '26 | Mar '26 | Apr '26 | May '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 2 | 2 | 2 | 2 | 2 |
| Buy | 5 | 5 | 5 | 5 | 5 | 4 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 7 | 7 | 7 | 7 | 7 | 6 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $8 → $13 | Strong Buy | Maintains | $8 → $13 | +74.03% | May 6, 2026 |
| Piper Sandler | Piper Sandler | Buy Reiterates $8 → $16 | Buy | Reiterates | $8 → $16 | +114.19% | Apr 27, 2026 |
| Piper Sandler | Piper Sandler | Buy Reiterates $12 → $8 | Buy | Reiterates | $12 → $8 | +7.10% | Mar 30, 2026 |
| Baird | Baird | Buy Maintains $21 → $15 | Buy | Maintains | $21 → $15 | +100.80% | Mar 25, 2026 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $15 → $8 | Strong Buy | Maintains | $15 → $8 | +7.10% | Mar 25, 2026 |
Financial Forecast
Revenue This Year
141.09M
from 146.07M
Decreased by -3.41%
Revenue Next Year
164.61M
from 141.09M
Increased by 16.67%
EPS This Year
-4.39
from -17.93
EPS Next Year
-3.77
from -4.39
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | 165.7M | 201.1M | ||||||
| Avg | 141.1M | 164.6M | ||||||
| Low | 128.6M | 124.9M |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | 13.4% | 42.5% | ||||||
| Avg | -3.4% | 16.7% | ||||||
| Low | -12.0% | -11.5% |
EPS Forecast
| EPS | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | -3.33 | -1.71 | ||||||
| Avg | -4.39 | -3.77 | ||||||
| Low | -6.10 | -6.19 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | - | - | ||||||
| Avg | - | - | ||||||
| Low | - | - |
Sources: Price targets and consensus ratings provided by S&P Global Market Intelligence. Historical ratings and analyst data provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data sources.